Why pharma companies should not be allowed to continue funding medical education and doctors' participation in conferences

Why pharma companies should not be allowed to continue funding medical education and doctors' participation in conferences

Bibliographic Details
Main Author:	Sandhya Srinivasan
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2023-01-01
Series:	Journal of Medical Evidence
Online Access:	http://www.journaljme.org/article.asp?issn=2667-0720;year=2023;volume=4;issue=3;spage=268;epage=270;aulast=Srinivasan

Similar Items

Why pharma companies should be allowed to continue to fund medical conferences and doctors' attendance
by: Anil Arora, et al.
Published: (2023-01-01)

Should Pharma Companies Waive Their COVID-19 Vaccine Patents? A Legal and Ethical Appraisal
by: Tammy Cowart, et al.
Published: (2023-05-01)

Words for pharma: a quantitative and qualitative analysis on vision, mission and values of multinational pharma companies.
by: Giulio Zuanetti, et al.
Published: (2020-04-01)

Why we should allow performance enhancing drugs in sport.
by: Savulescu, J, et al.
Published: (2004)

Bridging the Strategic Gap Between Biotech and Pharma Companies
by: Gudrun Tiedemann
Published: (2004-11-01)

Why should we continue to learn?
by: Karl Golnik
Published: (2017-05-01)

Proactive Approach to Occupational Hygiene in a Pharma Formulation Company
by: Apexa Thaker, et al.
Published: (2022-01-01)

Utilization of IT in Pakistan and MNC Pharma. Companies in the Korangi Industrial Area
by: Raza Kamal, et al.
Published: (2006-01-01)

Why Company Should Adopt Integrated Reporting?
by: Mohammad Enamul Hoque
Published: (2017-01-01)

Why Company Should Adopt Integrated Reporting?
by: Mohammad Enamul Hoque
Published: (2017-03-01)

Why Company Should Adopt Integrated Reporting?
by: Mohammad Enamul Hoque
Published: (2017-01-01)

Why Company Should Adopt Integrated Reporting?
by: Mohammad Enamul Hoque
Published: (2017-01-01)

PharmaSynth AS
by: Pirkko Irene Penttilä-Hiltunen
Published: (2023-11-01)

PharmaSynth AS
by: Pirkko Irene Penttilä-Hiltunen
Published: (2023-11-01)

Should not be allowed to ban
by: M. G. Malaev
Published: (2018-06-01)

Why Should Clinical Autopsies Continue to Exist?
by: Simone Gusmão Ramos, et al.
Published: (2021-08-01)

Guideline proposal for pharma companies to manage pharmacovigilance activities in digital media
by: Daniela Bernardini, et al.
Published: (2022-04-01)

Should tobacco and alcohol companies be allowed to influence Australia’s National Drug Strategy?
by: Becky Freeman, et al.
Published: (2017-04-01)

Research advocacy: why every scientist should participate.
by: Elizabeth Marincola
Published: (2003-12-01)

Pharma 4.0 Continuous mRNA Drug Products Manufacturing
by: Andreas Ouranidis, et al.
Published: (2021-08-01)

Training the next generation of Africa’s doctors: why medical schools should embrace the team-based learning pedagogy
by: Charles Okot Odongo, et al.
Published: (2019-11-01)

Élan Pharma SA
Published: (1995-05-01)

Élan Pharma SA
Published: (1995-05-01)

Cerbios-Pharma SA
Published: (1995-05-01)

Medicines without doctors: why the Global Fund must fund salaries of health workers to expand AIDS treatment.
by: Gorik Ooms, et al.
Published: (2007-04-01)

High Education Ministry fund raise allowance
by: Kwong Wah, Yit Poh
Published: (2013)

High Education Ministry fund raise allowance
by: Kwong Wah, Yit Poh
Published: (2013)

MEDICAL AFFAIRS EFFICIENCY IN PHARMA – A PRAGMATIC APPROACH TO SUCCESS
by: José Aleixo Dias
Published: (2014-12-01)

Food-pharma convergence in medical nutrition- best of both worlds?
by: Tamar C Weenen, et al.
Published: (2013-01-01)

Medical Affairs Efficiency in Pharma – a Pragmatic Approach to Success
by: José Aleixo Dias
Published: (2014-10-01)

Towards vaccine equity: Should big pharma waive intellectual property rights for COVID-19 vaccines?
by: Melody Okereke
Published: (2021-11-01)

SPER 3 rd annual conference on "Recent trends in pharma industry: Bridging the gaps in pharmaceutical education"
by: Upendra Nagaich
Published: (2014-01-01)

Why We Should Keep Studying Good (and Everyday) Participation: An Analogy to Political Participation
by: Neta Kligler-Vilenchik
Published: (2018-11-01)

A Qualitative Study on Development of Enriching Performance Management System at a Pharma-Company
by: Muhammad A. Khan, et al.
Published: (2018-06-01)

A Qualitative Study on Development of Enriching Performance Management System at a Pharma-Company
by: Muhammad A. Khan, et al.
Published: (2018-06-01)

An open source pharma roadmap.
by: Balasegaram, M, et al.
Published: (2017)

Extrusion for pharma applications: An update
by: Maël Gallas, et al.
Published: (2023-01-01)

An open source pharma roadmap.
by: Manica Balasegaram, et al.
Published: (2017-04-01)

Big Pharma, Big Business
by: Sorin-George Toma, et al.
Published: (2021-01-01)

Should teens be allowed to consent for vaccines?
by: John Lantos
Published: (2021-06-01)